Effect of the GLP-1 Analog Exendin-4 and Oxaliplatin on Intrahepatic Cholangiocarcinoma Cell Line and Mouse Model-Reference-Cited by-同舟云学术

Effect of the GLP-1 Analog Exendin-4 and Oxaliplatin on Intrahepatic Cholangiocarcinoma Cell Line and Mouse Model

Published:2013-12-13 Issue:12 Volume:14 Page:24293-24304
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Chen Ben-Dong,Zhao Wen-Chao,Jia Qing-An,Zhou Wen-Yan,Bu Yang,Wang Zuo-Zheng,Wang Feng,Wu Wu-Jun,Wang Qi

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/14/12/24293/pdf

Reference15 articles.

1. Mechanisms of action of glucagon-like peptide 1 in the pancreas;Doyle;Pharmacol. Ther,2007

2. The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes;Drucker;Lancet,2006

3. The physiology of glucagon-like peptide 1;Holst;Physiol. Rev,2007

4. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4;Arakawa;Diabetes,2010

5. Intrahepatic cholangiocarcinoma;Poultsides;Surg. Clin. N. Am,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucagon-like peptide 1 receptor agonist: A potential game changer for cholangiocarcinoma;World Journal of Gastroenterology;2024-09-14

2. Liraglutide exhibits potential anti-tumor effects on the progression of intrahepatic cholangiocarcinoma, in vitro and in vivo;Scientific Reports;2024-06-14

3. Suppressive effects of umbilical cord mesenchymal stem cell-derived exosomal miR-15a-5p on the progression of cholangiocarcinoma by inhibiting CHEK1 expression;Cell Death Discovery;2022-04-15

4. Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication;Canadian Journal of Diabetes;2021-04

5. Oxaliplatin reverses the GLP‑1R‑mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling;Oncology Letters;2019-06-19